Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 6/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796066 | 0.77 | MAPT (0.41) | CYP1A2CYP3A4CYP2C19NPC1RAB9A | |
| SCHEMBL27674685 | 0.75 | SYK (0.44) | PIK3C3CYP1A2CYP3A4CYP2C19SOD1 | |
| SCHEMBL23859941 | 0.72 | RAB9A (0.62) | CYP1A2CYP3A4CYP2C19NPC1RAB9A | |
| SCHEMBL343410 | 0.72 | PAK4 (0.54) | PIK3C3CLK4KDRAURKBMEN1 | |
| SCHEMBL4212835 | 0.71 | NPC1 (0.58) | CYP1A2CYP3A4CYP2C19NPC1RAB9A | |
| SCHEMBL4012756 | 0.71 | RAB9A (0.71) | CYP1A2CYP3A4CYP2C19NPC1RAB9A | |
| SCHEMBL4595367 | 0.71 | KDR (0.47) | CYP1A2NPC1RAB9ATP53CLK4 | |
| SCHEMBL16876539 | 0.71 | MAP4K4 (0.61) | NPC1RAB9AALDH1A1CLK4KDR | |
| SCHEMBL342602 | 0.71 | RAB9A (0.39) | PIK3C3CYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL16638038 | 0.71 | ROCK2 (0.61) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411010-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8492397-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8263632-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| CN-102497863-A | Novel aminopyridine derivatives having Aurora a selective inhibitory action | MSD KK | 2012-06-13 | — | — | CN | disclosed |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2411011-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| WO-2010111056-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | PIK3C3 1321/4885CYP1A2 3576/4885CYP3A4 2933/4885 |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | PIK3C3 1364/4885CYP1A2 1817/4885CYP3A4 1482/4885 |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | PIK3C3 1221/4885CYP1A2 3341/4885CYP3A4 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.